Skip to main content
. Author manuscript; available in PMC: 2022 Jul 6.
Published in final edited form as: Mol Cancer Res. 2021 Oct 5;20(1):62–76. doi: 10.1158/1541-7786.MCR-21-0108

Figure 3. GLI3 protein expression is elevated in SPOP mutant prostate cancer specimens.

Figure 3.

a Quantitative GLI3 IHC analysis from 86 cases of SPOP mutation-negative (n=74) and SPOP mutation-positive (n=12) prostate cancers. A single SPOP mutant Y87C tumor specimen (red dot) was excluded from statistical consideration. Significance was determined by two-tailed t-test. b Representative images of GLI3 IHC performed on one SPOP WT and two SPOP mutant (F133V and Y87C) prostate tumors. Note that GLI3 is not elevated in the SPOP mutant prostate tumor carrying a Y87C mutation that retains the ability to bind, ubiquitylate, and promote the degradation of GLI3. c GLI3 IHC scoring schema.